# Study Evaluating the Safety and Efficacy of AR-15512 (COMET-3)

> **NCT05360966** · PHASE3 · COMPLETED · sponsor: **Aerie Pharmaceuticals** · enrollment: 467 (actual)

## Conditions studied

- Dry Eye Disease

## Interventions

- **DRUG:** 0.003% AR-15512 ophthalmic solution
- **DRUG:** AR-15512 vehicle ophthalmic solution

## Key facts

- **NCT ID:** NCT05360966
- **Lead sponsor:** Aerie Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-07-18
- **Primary completion:** 2023-10-17
- **Final completion:** 2023-10-17
- **Target enrollment:** 467 (ACTUAL)
- **Last updated:** 2025-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05360966

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05360966, "Study Evaluating the Safety and Efficacy of AR-15512 (COMET-3)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05360966. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*